Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss

Trial Profile

A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs LY 3056480 (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms REGAIN
  • Sponsors Audion Therapeutics
  • Most Recent Events

    • 23 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top